by April Breyer Menon | Feb 1, 2021
As part of the “Consolidated Appropriations Act, 2021,” a COVID-19 relief and spending bill, 42 U.S.C. § 262(k) was amended to include new provisions for the FDA’s Database of Licensed Biological Products (“Purple Book”). According to the new legislation, within 180...
by April Breyer Menon | Jan 12, 2021
Download PDF Download...
by April Breyer Menon | Jan 3, 2021
Venable Fizpatrick partner Ha Kung Wong spoke with Law360 for an article analyzing the patent cases to watch in 2021, including U.S. v. Arthrex, which involves the constitutionality of how administrative patent law judges who preside over inter partes review (IPR) and...
by April Breyer Menon | Dec 30, 2020
The Center for Biosimilars’ “Not So Different” podcast “Biosimilar Law Experts Discuss Potential Bills and Chances for Passage” featuring Venable Fizpatrick’s Ha Kung Wong and April Breyer Menon, was one of the series’...
by April Breyer Menon | Dec 29, 2020
Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article discussing what to expect for biosimilars in 2021, including the potential for the first authorized biologics, and the Arthrex v. Smith & Nephew case pending at the...